Clinical Trial Update: CPX-351 Therapy for MDS After Hypomethylating Agent Failure [Phase 2]

View source ↗

Summary

Phase 2 trial of CPX-351 for myelodysplastic syndrome after failure of hypomethylating agents was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: TERMINATED | Results posted: 2024-08-15